Ensayo clínico comparando propofol versus propofol más midazolam en endoscopia diagnóstica en pacientes de bajo riesgo anestésico
- Laura Julián Gómez 1
- A. M. Fuentes Coronel 1
- C. López Ramos 1
- Carlos Ochoa Sangrador 1
- Paola Fradejas Salazar 1
- Eva Purificación Martín Garrido 1
- P. Conde Gacho 1
- María del Carmen Bailador Andrés 1
- María García Alvarado 1
- Gabriela Rascarachi 1
- Rocio Silvana Castillo Trujillo 1
- S. J. Rodríguez Gómez 1
- 1 Hospital Virgen de la Concha. Zamora
ISSN: 2340-416, 1130-0108
Année de publication: 2018
Volumen: 110
Número: 11
Pages: 691-698
Type: Article
D'autres publications dans: Revista Española de Enfermedades Digestivas
Résumé
Background and objectives: propofol and midazolam are two of the most commonly used sedatives in upper gastrointestinal endoscopy (UGE). The objective of this study was to evaluate these two sedation regimens administered to patients who underwent an UGE with regard to security, efficiency, quality of exploration and patient response. Patients and methods: a prospective, randomized and double-blind study was performed which included 83 patients between 18 and 80 years of age of a low anesthetic risk (ASA - American Society of Anesthesiologists- I-II) who underwent a diagnostic UGE. Patients were randomized to receive sedation with either placebo plus propofol (group A) or midazolam plus propofol (group B). Results: in group A, 42 patients received a placebo bolus (saline solution) and on average up to 115 mg of propofol in boluses of 20 mg. In group B, 41 patients received 3 mg of midazolam and an average of up to 83 mg of propofol in boluses of 20 mg. There were no significant differences in the adverse effects observed in either group and all adverse events were treated conservatively. The patients in group B (midazolam plus propofol) entered the desired sedated state more quickly with no variation in the overall time of the exploration. The quality of the endoscopic evaluation was similar in both groups and the patients were equally satisfied regardless of the sedatives they received. Conclusions: the use of midazolam plus propofol as a sedative does not affect the overall exploration time, a lower dose of propofol can be used and it is as safe as administering propofol as a monotherapy while providing the same level of both exploration quality and patient approval.